Molecular characterisation and genetic diversity of canine parvovirus type 2 prevalent in Central China

Hu, Wen; Xu, Xin; Liu, Qiang; Ji, Jun; Kan, Yunchao; Yao, Lunguang; Bi, Yingzuo; Xie, Qingmei

doi:10.2478/jvetres-2020-0056

Figures & Tables

Detection of CPV-VP2 strains by electrophoresis. M – 2000 Maker; 1-9 – CN/HN1601-1607, CN/HN1708, and CN/HN1709; N – negative control

Geographical distribution and genotype of CPV isolates obtained in the study

Tertiary structural model of canine parvovirus (CPV) capsid protein (VP2) and the distribution of the main amino acid mutation residues. (a) – conserved structure of VP2 and (b) – structure of the mutant VP2 protein

Phylogenetic tree based on VP2 gene sequences of canine parvovirus type 2 (CPV-2). Strains isolated from four central Chinese provinces in this study are marked with coloured triangles. The strains isolated from Hubei Province are indicated by black triangles; those from Anhui blue; those from Henan by orange; and those from Jiangsu green

Information about the reference strains in our study

Strain	Accession no.	Genotype	Place of isolation	Submission date
nn171025	MK332005	CPV-2a	Guangxi	2017
nn17101	MK332003	CPV-2a	Guangxi	2017
nn1693	MK332002	CPV-2b	Guangxi	2016
nn1681	MK331996	CPV-2b	Guangxi	2016
nn171105	MK332007	CPV-2c	Guangxi	2017
nn171024	MK332004	CPV-2c	Guangxi	2017
CPV-411b.us.9	EU659121	CPV-2b	the USA	1998
CPV-13.us.81	EU659118	CPV-2a	the USA	1981
CPV-6.us.80	EU659117	CPV-2	the USA	1980
Raccoon/ WI/ 37/ 10	JN867618	CPV-2a	the USA	2010
110/ 07-27	FJ005236	CPV-2c	the USA	2007
08-B	GU362934	CPV-2a	Italy	2008
260-00	MF177231	CPV-2a	Italy	2000
140/ 05	FJ005265	CPV-2b	Italy	2005
CPV /IZSSI /25835/ 09	KU508407	CPV-2c	Italy	2009
56/00	FJ222821	CPV-2c	Italy	2000
CPV/dog/HCM/20/2013	LC216910	CPV-2c	Indonesia	2013
Pome	EF599098	CPV2c(a)	South Korea	2007
DH326	EF599097	CPV-2b	South Korea	2007
DH426	EF599096	CPV-2a	South Korea	2007
16M130	MH643886	CPV-2	South Korea	2016
2670/CPV-2c/2010/Ind	KX425920	CPV-2c	India	2010
CU267	MH711901	CPV-2c	Thailand	2017
TH011401	KT364589	CPV-2c	Thailand	2014
T37	CPU72698	CPV-2a	Taiwan	1996
T10	CPU72696	CPV-2b	Taiwan	1996
2017090801	MH127909	CPV-2c	Taiwan	2017
Protein(VP2)	KU244254	CPV-2c	Taiwan	2015
PV/PL/HeN02/08	EU441280	CPV-2a	Henan	2008
Henan42	KJ438805	CPV-2a	Henan	2013
CPV-HN1617	MF467229	CPV-2c	Henan	2016
CPV-zj18	KM386948	CPV-2b	Zhejiang	2014
CPV-zj7	KM386937	CPV-2a	Zhejiang	2014
Beijing	HQ883267	CPV-2a	Beijing	2010
BJ-1	MN101726	CPV-2a	Beijing	2018
2011-BJ-B43	KF803527	CPV-2b	Beijing	2011
2011-BJ-B6	KF803606	CPV-2b	Beijing	2011
CPV-SH1516	MG013488	CPV-2c	Shanghai	2017
Shanghai/04g/2016	KY937646	CPV-2a	Shanghai	2016
ShangHai/3-2/2016	KY937640	CPV2a	Shanghai	2016
Shanghai/03g/2016	KY937637	CPV-2c	Shanghai	2016
CPVpf/2007(vaccine)	FJ197847	CPV-2	South Korea	2007
29/97(vaccine)	FJ222823	CPV-2b	N.I. no information	2008
CPV-GX1581	MF467242	CPV-2c	Guangxi	2015
CPV-HN1506	MF467240	New-2a	Henan	2017
RVC57 KNA 2016	KY399053	New-2a	Saint Kitts and Nevis	2016
SY40	KY625992	New-2a	China	2016
PU4	KC429669	New-2a	India	2011
BJ15-15	KT162046	New-2a	Beijing	2015
SY38	KY625998	New-2b	China	2016
BJ15-11	KT162026	New-2b	Beijing	2015
VP2	KR058183	New-2b	China	2013
CPV-HN1506	MF467239	New-2b	Henan	2015

Epidemiological data of the 56 strains in the study and the reference strains for genotyping

Strains	Accession nos.	Origin	Vaccination record	Age	CPV type	Substitution of amino acid residues in VP2

						5	267	297	324	370	426	440
CPV-6.us.80	EU659117	the USA, 1980	N.I. no information	N.I.	CPV-2	A	F	S	Y	Q	N	T
CPV-13.us.81	EU659118	the USA, 1981	N.I.	N.I.	CPV-2a	A	F	S	Y	Q	N	A
CPV-411b.us.98	EU659121	the USA, 1998	N.I.	N.I.	CPV-2b	A	F	A	Y	Q	N	A
CPV-HN1506	MF467240	Henan, 2017	N.I.	N.I.	New-2a	A	Y	A	I	Q	N	A
RVC57 KNA	KY399053	SNA, 2016	N.I.	N.I.	New-2a	A	F	A	I	Q	N	A
BJ15-15	KT162046	Beijing, 2015	N.I.	N.I.	New-2a	A	Y	A	I	Q	N	A
BJ15-11	KT162026	Beijing, 2015	N.I.	N.I.	New-2b	A	Y	A	I	Q	D	A
VP2	KR058183	China, 2013	N.I.	N.I.	New-2b	A	Y	A	I	Q	D	A
CPV-HN1506	MF467239	Henan, 2015	N.I.	N.I.	New-2b	A	Y	A	I	Q	D	A
CPV dog HCM	LC216910	Indonesia,2013	N.I.	N.I.	CPV-2c	G	Y	A	I	R	E	T
CPV-HN1617	MF467229	Henan, 2016	N.I.	N.I.	CPV-2c	G	Y	A	I	R	E	T
CPV-SH1516	MG013488	Shanghai, 2017	N.I.	N.I.	CPV-2c	G	Y	A	I	R	E	T
CN/HN1601	MK517966	Henan, 2016	N.I.	3 m	CPV-2c	A	Y	A	I	R	E	T
CN/HN1602	MK517967	Henan, 2016	1 dose	2 m	CPV-2c	A	Y	A	I	R	E	T
CN/HN1603	MK517968	Henan, 2016	2 doses	5 m	CPV-2c	G	Y	A	I	R	E	T
CN/HN1604	MK517969	Henan, 2016	1 dose	2 m	CPV-2c	A	Y	A	I	R	E	T
CN/HN1605	MK517970	Henan, 2016	1 dose	2 m	CPV-2c	G	Y	A	I	R	E	T
CN/HN1606	MK517971	Henan, 2016	2 doses	7 m	New-2a	A	Y	A	I	Q	N	A
CN/HN1607	MK517972	Henan, 2016	1 dose	2 m	CPV-2c	G	Y	A	I	R	E	T
CN/HN1708	MK517973	Henan, 2017	N.I.	3 m	CPV-2c	A	Y	A	I	R	E	T
CN/HN1709	MK517974	Henan, 2017	N.I.	4 m	New-2a	A	Y	A	I	Q	N	A
CN/HN1710	MK517975	Henan, 2017	1 dose	3 m	New -2a	A	Y	A	I	Q	N	A
CN/HN1711	MK517976	Henan, 2017	1 dose	2 m	CPV-2c	A	Y	A	I	R	E	T
CN/HN1712	MK517977	Henan, 2017	N.I.	5 m	New-2a	A	Y	A	I	Q	N	A
CN/HN1713	MK517978	Henan, 2017	1 dose	42 d	CPV-2c	G	Y	A	L	R	E	T
CN/HN1714	MK517979	Henan, 2017	1 dose	2 m	CPV-2c	A	Y	A	Y	R	E	T
CN/HN1715	MK517980	Henan, 2017	1 dose	5 m	New-2a	A	Y	A	I	Q	N	A
CN/HN1716	MK517981	Henan, 2017	2 doses	4 m	CPV-2c	G	Y	A	I	R	E	T
CN/HN1717	MK517982	Henan, 2017	N.I.	2 m	New-2a	G	Y	A	I	Q	N	A
CN/HN1718	MK517983	Henan, 2017	1 dose	37 d	New-2b	A	Y	A	I	Q	D	A
CN/HN1719	MK517984	Henan, 2017	1 dose	2 m	New-2b	A	Y	A	I	Q	D	A
CN/HN1720	MK517985	Henan, 2017	2 doses	4 m	New-2a	G	Y	A	I	Q	N	A
CN/HN1721	MK517986	Henan, 2017	1 dose	2 m	CPV-2c	G	Y	A	I	R	E	T
CN/HN1722	MK517987	Henan, 2017	N.I.	6 m	CPV-2c	A	Y	A	I	R	E	T
CN/HN1723	MK517988	Henan, 2017	1 dose	5 m	CPV-2c	A	Y	A	I	R	E	T
CN/HB1601	MK517989	Hubei, 2016	N.I.	40 d	CPV-2c	G	Y	A	I	R	E	T
CN/HB1602	MK517990	Hubei, 2016	1 dose	5 m	CPV-2c	G	Y	A	I	R	E	T
CN/HB1603	MK517991	Hubei, 2016	1 dose	3 m	CPV-2c	G	Y	A	I	R	E	T
CN/HB1704	MK517992	Hubei, 2017	1 dose	3 m	CPV-2c	G	Y	A	I	R	E	A
CN/HB1705	MK517993	Hubei, 2017	2 doses	4 m	CPV-2c	A	Y	A	I	R	E	T
CN/HB1706	MK517994	Hubei, 2017	1 dose	2 m	CPV-2c	A	Y	A	I	R	E	T
CN/HB1707	MK517995	Hubei, 2017	N.I.	3 m	New-2a	A	Y	A	I	Q	N	A
CN/HB1708	MK517996	Hubei, 2017	1 dose	33 d	CPV-2c	A	Y	A	I	R	E	T
CN/HB1709	MK517997	Hubei, 2017	1 dose	2 m	CPV-2c	G	Y	A	I	R	E	T
CN/HB1710	MK517998	Hubei, 2017	2 doses	4 m	CPV-2c	G	Y	A	I	R	E	T
CN/HB1711	MK517999	Hubei, 2017	N.I.	6 m	CPV-2c	A	Y	A	I	R	E	T
CN/HB1712	MK518000	Hubei, 2017	1 dose	39 d	New-2a	A	Y	A	I	Q	N	A
CN/HB1713	MK518001	Hubei, 2017	1 dose	3 m	CPV-2c	G	Y	A	L	R	E	T
CN/HB1714	MK518002	Hubei, 2017	N.I.	5 m	CPV-2a	A	Y	S	Y	Q	N	T
CN/HB1715	MK518003	Hubei, 2017	1 dose	2 m	New-2a	G	Y	A	I	R	E	T
CN/AH1601	MK518004	Anhui, 2016	2 doses	6 m	CPV-2c	G	Y	A	I	R	E	T
CN/AH1602	MK518005	Anhui, 2016	N.I.	4 m	CPV-2c	G	Y	A	I	R	E	T
CN/AH1603	MK518006	Anhui, 2016	1 dose	3 m	CPV-2c	G	Y	A	I	R	E	T
CN/AH1604	MK518007	Anhui, 2016	1 dose	5 m	New-2b	A	Y	A	I	R	D	T
CN/AH1705	MK518008	Anhui, 2017	N.I.	8 m	CPV-2c	G	Y	A	I	R	E	T
CN/AH1706	MK518009	Anhui, 2017	1 dose	3 m	New-2b	A	Y	A	I	Q	D	A
CN/AH1707	MK518010	Anhui, 2017	N.I.	2 m	CPV-2c	A	Y	A	I	R	E	T
CN/AH1708	MK518011	Anhui, 2017	N.I.	3 m	New-2b	G	Y	A	I	Q	D	T
CN/AH1709	MK518012	Anhui, 2017	2 doses	4 m	CPV-2c	A	Y	A	I	R	E	T
CN/AH1710	MK518013	Anhui, 2017	1 dose	5 m	New -2a	G	Y	A	I	Q	N	T
CN/JS1601	MK518014	Jiangsu, 2016	N.I.	3 m	CPV-2c	A	Y	A	I	R	E	T
CN/JS1602	MK518015	Jiangsu, 2016	1 dose	2 m	CPV-2c	G	Y	A	I	R	E	T
CN/JS1603	MK518016	Jiangsu, 2016	N.I.	41 d	New-2a	A	Y	A	I	Q	N	A
CN/JS1704	MK518017	Jiangsu, 2017	N.I.	4 m	New-2a	G	Y	A	I	Q	N	A
CN/JS1705	MK518018	Jiangsu, 2017	1 dose	4 m	CPV-2c	A	Y	A	I	R	E	T
CN/JS1706	MK518019	Jiangsu, 2017	N.I.	2 m	CPV-2c	A	Y	A	I	R	E	T
CN/JS1707	MK518020	Jiangsu, 2017	2 doses	5 m	CPV-2c	G	Y	A	I	R	E	T
CN/JS1708	MK518021	Jiangsu, 2017	1 dose	3 m	CPV-2c	A	Y	A	I	R	E	T

Molecular characterisation and genetic diversity of canine parvovirus type 2 prevalent in Central China

Figures & Tables

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Information about the reference strains in our study

Epidemiological data of the 56 strains in the study and the reference strains for genotyping

Paradigm

My account